Lessons Learned from Leading Healthcare Institutions

July 23, 2019

Improving outcomes and reducing cost for the treatment of sepsis patients while enhancing your Antimicrobial Stewardship Program is a challenge. Faster antimicrobial susceptibility results can improve patient outcomes and quality measures.

Spotlight

USV PRIVATE LIMITED

We are a 55 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Our product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India. We market our products globally to 75 countries. In the financial year 2015-16, our total income was Rs 25,445 million. Our Indian business contributed 82% to the revenue and the rest was from export of APIs and Finished Dosages. In India we are recognised for our leadership in the Oral Anti-Diabetic market where we rank No. 1 by Rx and Value. In the Cardiovascular diseases segment we are No. 1 by Rx and rank no. 6 by Value . We also have a significant presence in the areas of Vitamins, Minerals, Nutrients, Dermatology, Gastroenterology and CNS.

OTHER WHITEPAPERS
news image

working together to improve health and social care for all

whitePaper | February 11, 2022

We are living through the greatest challenge our health and care system has ever faced. The Coronavirus (Covid-19) pandemic caused an unprecedented external shock,

Read More
news image

The cultural shift to smart manufacturing in the medical device industry

whitePaper | February 22, 2023

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier.

Read More
news image

Three Challenges Facing Study Start Up and the Low-Code Automation Solution

whitePaper | November 24, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies

Read More
news image

NowCoping with healthcare's talent shortage — 10 must-reads

whitePaper | December 10, 2022

Healthcare’s workforce is in crisis. Waves of employee departures amid a once-in-a-century public health crisis have left hospitals all over the nation scrambling to fill critical roles across the enterprise.

Read More
news image

2022 Global Predictions Whitepaper

whitePaper | January 14, 2022

In the past year, more than nine billion doses of coronavirus vaccines have been administered, in at least 197 countries worldwide according to the BBC and Oxford University.

Read More
news image

Keeping Pace with the Healthcare Revolution

whitePaper | August 25, 2022

As the market enters the post-pandemic era, payers and providers are tasked with providing a customer and employee experience that keeps pace with that offered by a new wave of digital-native challengers.

Read More

Spotlight

USV PRIVATE LIMITED

We are a 55 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Our product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India. We market our products globally to 75 countries. In the financial year 2015-16, our total income was Rs 25,445 million. Our Indian business contributed 82% to the revenue and the rest was from export of APIs and Finished Dosages. In India we are recognised for our leadership in the Oral Anti-Diabetic market where we rank No. 1 by Rx and Value. In the Cardiovascular diseases segment we are No. 1 by Rx and rank no. 6 by Value . We also have a significant presence in the areas of Vitamins, Minerals, Nutrients, Dermatology, Gastroenterology and CNS.

Events